Clinical Updates in Multiple Myeloma From San Diego

Clinical Updates in Multiple Myeloma From San Diego is organized by Integrity Continuing Education Inc..

Release Date: January 11, 2024
Expiration Date: January 11, 2025

Program Overview:
This activity will provide context and insight on the latest data in multiple myeloma and precursor conditions released at the recent meeting in San Diego, led by expert faculty, Dr. Ola Landgren and Dr. Saad Usmani.?The following abstracts will be covered:

Relapsed/Refractory Multiple Myeloma (RRMM)

• Oral Abstract 1021 – The Phase 2 CARTITUDE-2 Trial: Updated Efficacy and Safety of Ciltacabtagene Autoleucel in Patients with Multiple Myeloma and 1-3 Prior Lines of Therapy (Cohort A) and with Early Relapse after First Line Treatment (Cohort B)
• Oral Abstract 542 – Real-World Results: Treatment Patterns and Clinical Outcomes Among Triple-Class– and BCMA-Exposed Multiple Myeloma
• Oral Abstract 91 – Real-World Outcomes With Teclistamab for Heavily-Pretreated Relapsed-Refractory Multiple Myeloma
• Oral Abstract 1023 – Phase 1 Study of CART-Ddbcma for the Treatment of Patients with Relapsed and/or Refractory Multiple Myeloma: Results from at Least 1-Year Follow-up in All Patients
• Phase 1 Study of CART-Ddbcma for the Treatment of Patients with Relapsed and/or Refractory Multiple Myeloma: Results from at Least 1-Year Follow-up in All Patients

Newly-Diagnosed Multiple Myeloma (NDMM)

• Oral Abstract 210 – Efficacy and Safety of Daratumumab (DARA) Monotherapy in Patients with Intermediate-Risk or High-Risk Smoldering Multiple Myeloma (SMM): Final Analysis of the Phase 2 Centaurus Study
• Oral Abstract LBA-1 – PERSEUS  – Phase 3 Randomized Study of Daratumumab (DARA) + Bortezomib, Lenalidomide, and Dexamethasone (VRd) Versus Vrd Alone in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Who Are
• Eligible for Autologous Stem Cell Transplantation (ASCT): Primary Results of the Perseus Trial
• Oral Abstract 4 – Iskia esults of the Phase III Randomized Iskia Trial: Isatuximab-Carfilzomib-Lenalidomide-Dexamethasone Vs Carfilzomib-Lenalidomide-Dexamethasone As Pre-Transplant Induction and Post-Transplant Consolidation in Newly Diagnosed Multiple Myeloma Patients

Learning Objectives:
Upon completion of this educational activity, participants should be able to:

• Compare and contrast new and emerging therapies with established treatment options
• Identify patients that could potentially benefit from referral to a clinical trial